Obermatt
See Similar Stocks →

Compugen

NAQ:CGEN · IL0010852080
BiotechnologySmall

360° View

19
Price/Sales15
Price/Earnings63
Price/Book29
Dividend Yield1
Revenue Growth4
Profit Growth46
Capital Growth53
TSR 52w61
Leverage71
Liquidity32
Refinancing10
Combined8
Analyst Opinions100
Pro Holdings35
Opinion Changes50
Market Pulse15

Profile

CountryIsrael
IndustryBiotechnology
SizeSmall
TypePublic Company
ExchangeNASDAQCM
Founded1993
Employees84
Websitecgen.com
ISINIL0010852080
Last UpdateApr 2, 2026
Index & Theme
ImmunologyOncologyCloud ComputingHealth CareInformation TechnologyProfessional ServicesProject Management

Description

Compugen Ltd. operates as a clinical-stage therapeutic discovery and development company utilizing its AI/ML powered predictive computational discovery platform, to identify novel drug targets and to develop therapeutics in the field of cancer immuno…

Analysis

Compugen's 360° View rank of 19 places it among the weakest overall — better than 19% of its true peers.

It's growing slowly (34) and expensive versus peers (15). On safety it is carrying more balance-sheet risk (29), and the market shows muted sentiment (47). Taken together, its Combined rank of 8 reads as among the weakest overall.

Detailed & Historical Ranks

Deep dive into 15 detailed ranks and 3 years of history.

Current202520242023
Price/Sales
15
—
—
10
Price/Earnings
63
—
—
14
Price/Book
29
—
—
94
Dividend Yield
1
—
—
1
Value (overall)
15
—
—
41

Cells are coloured by rank band (red weak → green strong). Sentiment & 360° history begins 2023.

Similar Stocks

The companies this stock is ranked against.

Compare Compugen with its peers
Centessa Pharmaceuticals
NSQ:CNTA
28
CountryUK
IndustryBiotechnology
SizeSmall
Full Stock Analysis →
OSE Immunotherapeutics
PAR:OSE
31
CountryFrance
IndustryBiotechnology
SizeSmall
Full Stock Analysis →
Genmab
CPH:GMAB
40
CountryDenmark
IndustryBiotechnology
SizeLarge
Full Stock Analysis →
Prothena Corporation
NSQ:PRTA
39
CountryIreland
IndustryBiotechnology
SizeSmall
Full Stock Analysis →
Inventiva
PAR:IVA
16
CountryFrance
IndustryBiotechnology
SizeSmall
Full Stock Analysis →
AC Immune
NMQ:ACIU
68
CountrySwitzerland
IndustryBiotechnology
SizeSmall
Full Stock Analysis →

Make Sense of the Ranks

Every rank runs 1–100 against true peers. Higher is always better.

360° View
1 · Watch OutGood· 100
Value
1 · ExpensiveGood Value· 100
Quality
1 · Weak FundamentalsHigh Quality· 100
Growth
1 · Tough TimesHigh Growth· 100
Safety
1 · High LeverageWell-Financed· 100
Sentiment
1 · SkepticismPositive· 100
Learn More →